Briacell Therapeutics Corp (BCT : TSX)
Common Stock
$5.33
CAD
-0.25 (-4.48%)
Last updated: 2026-07-13
BCT
Briacell Therapeutics Corp
WealthAwesomePerformance
1 Day
-4.48%
1 Week
+6.60%
1 Month
+40.26%
YTD
-45.72%
Key Statistics
Market Cap
$48.54M
52W High
$27.20
52W Low
$3.68
P/E Ratio
-
50 Day MA
$4.78
200 Day MA
$8.78
Beta
1.54
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/13/2026 | $5.44 | $5.47 | $5.27 | $5.33 | $5.33 | 7,357 |
| 7/10/2026 | $5.30 | $5.64 | $5.30 | $5.58 | $5.58 | 14,492 |
| 7/9/2026 | $5.28 | $5.41 | $5.10 | $5.17 | $5.17 | 6,875 |
| 7/8/2026 | $4.84 | $5.38 | $4.84 | $5.27 | $5.27 | 22,074 |
| 7/7/2026 | $5.02 | $5.06 | $4.86 | $4.92 | $4.92 | 6,434 |
| 7/6/2026 | $4.82 | $5.26 | $4.82 | $5.00 | $5.00 | 11,884 |
| 7/3/2026 | $4.45 | $5.00 | $4.45 | $4.55 | $4.55 | 1,800 |
| 7/2/2026 | $4.85 | $4.85 | $4.41 | $4.64 | $4.64 | 5,467 |
| 6/30/2026 | $4.43 | $4.72 | $4.43 | $4.64 | $4.64 | 2,100 |
| 6/29/2026 | $4.36 | $4.58 | $4.36 | $4.42 | $4.42 | 5,970 |
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 275.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+275.2% Upside
Current Price
C$5.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
64.8%
Annualized
90-Day Vol
87.4%
Annualized
Trend (90d)
-43.4%
Annualized drift
90d Mean
C$4.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.06 | C$4.05 – C$6.33 |
| 60 trading days | C$4.81 | C$3.50 – C$6.59 |
| 90 trading days | C$4.56 | C$3.10 – C$6.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-31.92M
- Profit Margin
- 0.00%
- ROE (TTM)
- -175.26%
- EPS (Diluted)
- -1.19
- Book Value
- 4.70
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-10
Aug 25, 2025
1-for-15
Jan 29, 2025
1009-for-1000
Sep 5, 2023
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About BCT
Articles Featuring BCT.TO
Latest articles and analysis covering BCT.TO
Why Briacell Therapeutics Corp stock is sliding today
Briacell Therapeutics Corp's stock fell by 2.25% yesterday, closing at CA$5.21, as the company engages consulting firms to evaluate market access for its cancer treatment.
What's Going On With Briacell Therapeutics Corp Stock Tuesday?
Briacell Therapeutics Corp has experienced a notable uptick in its stock price, increasing by 22.64% over the past week. The company has also engaged consulting and branding firms to enhance its market access evaluation.
Why Briacell Therapeutics Corp stock is skyrocketing today
Briacell Therapeutics Corp's stock surged nearly 8% in a single trading day, driven by strategic partnerships aimed at enhancing market access for its cancer therapy, Bria-IMT.
Why Briacell Therapeutics Corp stock is skyrocketing today
Briacell Therapeutics Corp's stock jumped 5.22% today, driven by the company's strategic engagements aimed at advancing its cancer treatment, Bria-IMT, through market access evaluations and branding efforts.
Why Briacell Therapeutics Corp stock is skyrocketing today
Briacell Therapeutics Corp's stock surged by 7.11% in the latest trading session, driven by significant strategic moves aimed at enhancing its commercial readiness for its cancer immunotherapy product, Bria-IMT.
Why Briacell Therapeutics Corp stock is skyrocketing today
Briacell Therapeutics Corp (BCT.TO) experienced a significant stock price increase of 7.11% in the last trading session, fueled by strategic partnerships aimed at advancing its cancer therapy, Bria-IMT.
Why Briacell Therapeutics Corp stock is tanking today
Briacell Therapeutics Corp's stock has dropped 1.94% today, closing at CA$4.55. This decline raises questions about the company's future amidst a lack of significant news.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp's stock has risen by 4.31% in the latest trading session, closing at CA$4.84. This increase is indicative of investor optimism surrounding the company's future developments.
Why Briacell Therapeutics Corp stock is sliding today
Briacell Therapeutics Corp's stock fell sharply today, driven by investor concerns over the company's future despite a promising partnership aimed at enhancing drug delivery.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp (BCT.TO) has seen its stock price rise by 4.98% due to a strategic partnership with Uneedle aimed at enhancing the administration of its lead candidate, Bria-IMT.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp has seen a notable uptick in its stock price following a significant partnership announcement with Uneedle, aimed at enhancing the administration of its lead cancer immunotherapy, Bria-IMT.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp's stock rose 3.68% today following the announcement of a partnership with Uneedle to enhance the administration of its lead cancer treatment, Bria-IMT. This collaboration is expected to improve patient experience and support commercial readiness.
Why Briacell Therapeutics Corp stock is sliding today
Briacell Therapeutics Corp's stock has taken a hit, dropping 2.09% in the last trading session. The company's recent partnership with Uneedle aims to enhance the administration of its lead drug candidate, Bria-IMT, but uncertainties around regulatory approval loom large.
Why Briacell Therapeutics Corp stock is gaining today
Briacell Therapeutics Corp's stock gained 1.89% in the latest trading session, closing at CA$4.31. This increase reflects a potential shift in investor sentiment as the company continues to innovate in personalized immunotherapy.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp's stock surged by 4.62% in the last trading session, closing at CA$4.30. This increase highlights investor confidence in the company's strategic moves and its innovative approach to cancer treatment.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp (BCT.TO) experienced a 4.05% increase in its stock price, closing at CA$4.11. This rise may reflect growing investor confidence in its innovative cancer therapies, particularly in the context of recent developments.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp's stock rose by 2.28% in the latest trading session, closing at CA$4.04. This uptick reflects increasing investor interest in the company's innovative cancer treatment solutions.
Why Briacell Therapeutics Corp stock is tanking today
Briacell Therapeutics Corp's stock has dropped 0.75% in the latest trading session, reflecting investor concerns amid a lack of significant news. With a market cap of CA$33.9 million, the company faces challenges in the competitive biotech sector.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp's stock has risen by 2.82% in the last session, closing at CA$4.01. This increase signals investor optimism surrounding the company's advancements in immunotherapy for cancer treatment.
Why Briacell Therapeutics Corp stock is rising today
Briacell Therapeutics Corp's stock has risen by 3.38% to CA$3.98, reflecting positive investor sentiment towards its innovative cancer treatments.
Showing latest 20 articles